Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Protalix biotherapeutics, inc. save search
Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease
Published: 2023-06-08 (Crawled : 13:00) - biospace.com/
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 0.41%
H: 1.02%
C: -4.51%
elfabrio disease approval
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease
Published: 2023-05-10 (Crawled : 10:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 3.42%
H: 2.65%
C: -2.65%
elfabrio fda rare disease approval treatment global
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Published: 2023-05-05 (Crawled : 12:00) - biospace.com/
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 4.17%
H: 1.43%
C: -6.57%
prx-102 rare disease authorization treatment global
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
Published: 2023-02-24 (Crawled : 21:00) - biospace.com/
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 0.59%
H: 15.2%
C: 6.43%
treatment rare global disease chmp positive
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
Published: 2022-12-05 (Crawled : 12:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 3.54%
H: 2.56%
C: 1.71%
treatment rare drug global disease application license food
Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102
Published: 2022-12-04 (Crawled : 16:20) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
| Email alert
Add to watchlist
prx-102 disease
Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease
Published: 2022-05-26 (Crawled : 21:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 0.0%
H: 4.55%
C: 3.64%
disease
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
Published: 2022-04-04 (Crawled : 11:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 43.81%
H: 32.45%
C: -1.32%
prx-102 treatment rare disease topline trial results
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease
Published: 2022-03-18 (Crawled : 11:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: 6.44%
H: 11.11%
C: 6.06%
prx-102 treatment rare trial therapeutics disease results iot prx012
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease
Published: 2022-02-24 (Crawled : 12:30) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: -5.77%
H: 3.69%
C: 1.25%
prx-102 treatment europe application rare therapeutics disease authorization iot submission prx012
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease
Published: 2021-10-15 (Crawled : 13:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: -2.4%
H: 3.28%
C: 0.82%
disease treatment iot trial prx012 rare
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease
Published: 2021-10-11 (Crawled : 11:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: -12.27%
H: 4.24%
C: -1.69%
disease treatment iot prx012 rare
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease
Published: 2021-06-02 (Crawled : 11:00) - prnewswire.com
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: -16.11%
H: 3.6%
C: -0.8%
disease treatment iot prx012 rare
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
Published: 2021-04-28 (Crawled : 07:00) - biospace.com/
PLX | $1.22 3.39% 180K
|
Health Services
|
| O: -42.54%
H: 31.34%
C: 17.31%
disease fda iot response rare
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.